Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Reference Study ID Number: GO44145 https://forpatients.roche.com/ 888-662-6728
global-roche-genentech-trials@gene.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Back

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Recruiting

Open to: ALL

Age: 18.0 - 80.0

Blackpool Exeter Leicester London Nottingham Newcastle Barnet Canterbury London Southampton Leeds Oxford Glasgow

Medical Conditions

Lymphoma
Lymphoma, B-Cell

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2023 Dec 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Participants will receive intravenous (IV) glofitamab

Intervention Arm Group : Glofitamab + Pola-R-CHP;

Intervention Type : DRUG
Intervention Description : Participants will receive IV polatuzumab vedotin in combination with R-CHP

Intervention Arm Group : Glofitamab + Pola-R-CHP;Pola-R-CHP;

Intervention Type : DRUG
Intervention Description : Participants will receive IV rituximab

Intervention Arm Group : Glofitamab + Pola-R-CHP;Pola-R-CHP;

Intervention Type : DRUG
Intervention Description : Participants will receive cyclophosphamide as part of CHP chemotherapy

Intervention Arm Group : Glofitamab + Pola-R-CHP;Pola-R-CHP;

Intervention Type : DRUG
Intervention Description : Participants will receive IV doxorubicin

Intervention Arm Group : Glofitamab + Pola-R-CHP;Pola-R-CHP;

Intervention Type : DRUG
Intervention Description : Participants will receive oral prednisone as part of CHP chemotherapy

Intervention Arm Group : Glofitamab + Pola-R-CHP;Pola-R-CHP;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Blackpool Victoria Hospital
    Blackpool
    FY3 8NR
  • Royal Devon and Exeter Hospital
    Exeter
    EX2 5DW
  • Leicester Royal Infirmary
    Leicester
    LE1 5WW
  • Guy's Hospital
    London
    SE1 9RT
  • Nottingham University Hospitals NHS Trust
    Nottingham
    NG7 2UH
  • Newcastle University
    Newcastle
    NE1 4LP
  • Barnet Hospital
    Barnet
    EN5 3DJ
  • East Kent Hospitals University NHS Foundation Trust
    Canterbury
    CT1 3NG
  • University College London Hospitals NHS Foundation Trust - University College Hospital
    London
    NW1 2PG
  • Southampton General Hospital
    Southampton
    S016 6YD
  • Leeds Teaching Hosp NHS Trust
    Leeds
    LS9 7TF
  • Churchill Hospital - Oxford Cancer & Haematology Centre
    Oxford
    OX3 7LE
  • Beatson West of Scotland Cancer Centre
    Glasgow
    G12 0YN

Reference Study ID Number: GO44145 https://forpatients.roche.com/ 888-662-6728
global-roche-genentech-trials@gene.com



The study is sponsored by Hoffmann-La Roche



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06047080
Last updated 10 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top